Open Access

The diagnostic value of serum HE4 and CA-125 and ROMA index in ovarian cancer

  • Authors:
    • Su Wei
    • Hui Li
    • Bei Zhang
  • View Affiliations

  • Published online on: May 19, 2016     https://doi.org/10.3892/br.2016.682
  • Pages: 41-44
  • Copyright: © Wei et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Ovarian cancer is a common malignancy of the female reproductive system. Tumor markers serve as tools in the diagnosis of the disease. The aim of the present study was to determine the diagnostic value of sera levels of carbohydrate antigen-125 (CA-125), human epididymis protein 4 (HE4) as well as the area under the curve of the receiver operating characteristic (ROC) and the risk of ovarian malignancy algorithm (ROMA) index in ovarian cancer. The sera were measured using an electrochemiluminescence immunoassay on 158 individuals (64 patients with ovarian cancer, 64 with ovarian benign tumor and 30 healthy individuals) between September 2013 and May 2015. The results showed that levels of HE4 and CA‑125 in the sera of the ovarian benign tumor group as well as their ROMA index were significantly higher (P<0.05) than those of the ovarian benign tumor and control groups, regardless of pre‑ or postmenopausal status. However, the level of CA‑125 was significantly higher (P<0.05) in the ovarian benign tumor group compared with the healthy group, while the level of HE4 was similar in the two groups. The sensitivity of the ROMA index was higher (P<0.01) with detection of HE4 and CA‑125. In the ovarian cancer group, the areas under ROC curves of ROMA, HE4 and CA‑125 were 0.994, 0.990 and 0.941, respectively. The specificity and positive predictive value of HE4 in the premenopausal ovarian cancer group reached 98.36 and 95%, respectively. In conclusion, the results showed that the serum level of HE4 and the ROMA index are important indicators in the diagnosis of ovarian cancer. However, in addition to HE4 and CA‑125 detection, the ROMA index is extremely valuable in improving the diagnostic efficiency of ovarian cancer.

References

1 

Smith LH and Oi RH: Detection of malignant ovarian neoplasms: A review of the literature. I. Detection of the patient at risk; clinical, radiological and cytological detection. Obstet Gynecol Surv. 39:313–328. 1984. View Article : Google Scholar : PubMed/NCBI

2 

Zhang Z, Bast RC Jr, Yu Y, Li J, Sokoll LJ, Rai AJ, Rosenzweig JM, Cameron B, Wang YY, Meng XY, et al: Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 64:5882–5890. 2004. View Article : Google Scholar : PubMed/NCBI

3 

Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, Ngan HY, Pecorelli S and Beller U: Carcinoma of the fallopian tube. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 95(Suppl 1): S145–S160. 2006. View Article : Google Scholar : PubMed/NCBI

4 

Enakpene CA, Omigbodun AO, Goecke TW, Odukogbe AT and Beckmann MW: Preoperative evaluation and triage of women with suspicious adnexal masses using risk of malignancy index. J Obstet Gynaecol Res. 35:131–138. 2009. View Article : Google Scholar : PubMed/NCBI

5 

Karlsen MA, Sandhu N, Høgdall C, Christensen IJ, Nedergaard L, Lundvall L, Engelholm SA, Pedersen AT, Hartwell D, Lydolph M, et al: Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 127:379–383. 2012. View Article : Google Scholar : PubMed/NCBI

6 

Folk JJ, Botsford M and Musa AG: Monitoring cancer antigen 125 levels in induction chemotherapy for epithelial ovarian carcinoma and predicting outcome of second-look procedure. Gynecol Oncol. 57:178–182. 1995. View Article : Google Scholar : PubMed/NCBI

7 

Urban N, McIntosh MW, Andersen M and Karlan BY: Ovarian cancer screening. Hematol Oncol Clin North Am. 17:989–1005, ix. 2003. View Article : Google Scholar : PubMed/NCBI

8 

Jacobs I and Bast RC: The CA 125 tumour-associated antigen: A review of the literature. Hum Reprod. 4:1–12. 1989.PubMed/NCBI

9 

Moore RG, Brown AK, Miller MC, Badgwell D, Lu Z, Allard WJ, Granai CO, Bast RC and Lu K: Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol. 110:196–201. 2008. View Article : Google Scholar : PubMed/NCBI

10 

Levanon K, Crum C and Drapkin R: New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol. 26:5284–5293. 2008. View Article : Google Scholar : PubMed/NCBI

11 

Holcomb K, Vucetic Z, Miller MC and Knapp RC: Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women. Am J Obstet Gynecol. 205:358.e1–6. 2011. View Article : Google Scholar

12 

Hamed EO, Ahmed H, Sedeek OB, Mohammed AM, Abd-Alla AA and Abdel Ghaffar HM: Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response. Diagn Pathol. 8:112013. View Article : Google Scholar : PubMed/NCBI

13 

Kadija S, Stefanovic A, Jeremic K, Radojevic MM, Nikolic L, Markovic I and Atanackovic J: The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis. Int J Gynecol Cancer. 22:238–244. 2012. View Article : Google Scholar : PubMed/NCBI

14 

Sandri MT, Bottari F, Franchi D, Boveri S, Candiani M, Ronzoni S, Peiretti M, Radice D, Passerini R and Sideri M: Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: Correlation with pathological outcome. Gynecol Oncol. 128:233–238. 2013. View Article : Google Scholar : PubMed/NCBI

15 

Moore RG, Jabre-Raughley M, Brown AK, Robison KM, Miller MC, Allard WJ, Kurman RJ, Bast RC and Skates SJ: Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol. 203:228.e1–6. 2010. View Article : Google Scholar

16 

Park Y, Kim Y, Lee EY, Lee JH and Kim HS: Reference ranges for HE4 and CA125 in a large Asian population by automated assays and diagnostic performances for ovarian cancer. Int J Cancer. 130:1136–1144. 2012. View Article : Google Scholar : PubMed/NCBI

17 

Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, Gajewski W, Kurman R, Bast RC and Skates SJ: A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 112:40–46. 2009. View Article : Google Scholar : PubMed/NCBI

18 

Toss A, De Matteis E, Rossi E, Casa LD, Iannone A, Federico M and Cortesi L: Ovarian cancer: Can proteomics give new insights for therapy and diagnosis? Int J Mol Sci. 14:8271–8290. 2013. View Article : Google Scholar : PubMed/NCBI

19 

Yancik R: Ovarian cancer. Age contrasts in incidence, histology, disease stage at diagnosis, and mortality. Cancer. 71(Suppl 2): 517–523. 1993.PubMed/NCBI

20 

Molina R, Escudero JM, Augé JM, Filella X, Foj L, Torné A, Lejarcegui J and Pahisa J: HE4 a novel tumour marker for ovarian cancer: Comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases. Tumour Biol. 32:1087–1095. 2011. View Article : Google Scholar : PubMed/NCBI

21 

Lowe KA, Shah C, Wallace E, Anderson G, Paley P, McIntosh M, Andersen MR, Scholler N, Bergan L, Thorpe J, et al: Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev. 17:2480–2487. 2008. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

July 2016
Volume 5 Issue 1

Print ISSN: 2049-9434
Online ISSN:2049-9442

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Wei, S., Li, H., & Zhang, B. (2016). The diagnostic value of serum HE4 and CA-125 and ROMA index in ovarian cancer. Biomedical Reports, 5, 41-44. https://doi.org/10.3892/br.2016.682
MLA
Wei, S., Li, H., Zhang, B."The diagnostic value of serum HE4 and CA-125 and ROMA index in ovarian cancer". Biomedical Reports 5.1 (2016): 41-44.
Chicago
Wei, S., Li, H., Zhang, B."The diagnostic value of serum HE4 and CA-125 and ROMA index in ovarian cancer". Biomedical Reports 5, no. 1 (2016): 41-44. https://doi.org/10.3892/br.2016.682